Prediabetes Market Size Projected to Garner USD 375 Million by 2032 growing at 7.1% CAGR - Exclusive Report by Acumen Research and Consulting

Author: Acumen Research and Consulting

The Global Prediabetes Market Size is predicted to reach USD 375 Million by 2032 from USD 191 Million in 2022, at a CAGR of 7.1% between 2023 and 2032, as per the Acumen Research and Consulting

In recent years, the use of prediabetes as a critical concept in healthcare has been on the rise. Prediabetes refers to a condition in which blood sugar levels are higher than normal but not high enough to be classified as type 2 diabetes. Its significance lies in the fact that it serves as a warning sign, indicating an increased risk of developing type 2 diabetes, heart disease, and other related complications if left unmanaged. With the escalating global prevalence of type 2 diabetes and its associated health burdens, identifying individuals with prediabetes has become a priority for healthcare providers.

Healthcare professionals have increasingly recognized the importance of early detection and intervention in prediabetes to prevent or delay the onset of type 2 diabetes and its complications. As a result, screening guidelines have been updated to include recommendations for identifying individuals with prediabetes, such as routine blood glucose testing or the use of validated risk assessment tools. Moreover, there has been a growing emphasis on lifestyle modifications as a cornerstone of prediabetes management, including dietary changes, increased physical activity, weight loss, and behavior modification programs. Additionally, advancements in technology have facilitated the integration of prediabetes screening and management into routine clinical practice. Electronic health records and decision support systems help healthcare providers identify at-risk individuals and deliver targeted interventions. Telemedicine platforms and mobile health applications offer new avenues for delivering personalized education, monitoring progress, and providing ongoing support to individuals with prediabetes.

Prediabetes Market Analysis

Prediabetes Market Statistics

  • Global prediabetes market value was worth USD 191 Million in 2022, with a 7.1% CAGR from 2023 to 2032
  • North America prediabetes market share occupied around 41% in 2022
  • Asia-Pacific region is expected to expand at the highest CAGR between 2023 and 2032
  • By drug class, the diguanide segment captured the largest market share in 2022
  • Rising demand for wearable devices and mobile health applications for prediabetes management, propel the prediabetes market revenue

Request for a sample of this premium research report@

Prediabetes Market Trends

The prediabetes market has experienced significant growth in recent years, driven by several factors including the rising prevalence of prediabetes worldwide, increasing awareness about the condition, and a growing emphasis on preventive healthcare. As healthcare systems recognize the importance of early intervention to prevent the progression to type 2 diabetes and its associated complications, there has been a corresponding increase in demand for diagnostic tests, monitoring devices, and intervention programs targeting individuals with prediabetes.

One of the key drivers of market growth is the expanding range of diagnostic tools available for identifying individuals with prediabetes. Blood glucose testing, oral glucose tolerance tests, and glycated hemoglobin (HbA1c) assays are among the commonly used methods for diagnosing prediabetes. Additionally, advancements in technology have led to the development of innovative biomarkers and risk assessment tools that enable more accurate and efficient detection of prediabetes, further fueling market growth. Furthermore, the market for prediabetes management solutions, including lifestyle modification programs, dietary supplements, and digital health platforms, has been expanding rapidly. Healthcare providers and policymakers increasingly recognize the value of preventive interventions in reducing the economic and social burden of type 2 diabetes. Consequently, there has been growing investment in research and development to develop effective and scalable interventions for individuals with prediabetes, driving the prediabetes market growth.

Prediabetes Market Segmentation

Acumen Research and Consulting has segmented the global prediabetes market by drug class, age group, and region.

  • By drug class, the industry is categorized into diguanide, glucagon-like peptide-1 agonists (GLP-1), thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, and others.
  • By age group, the market is classified into children (12-18 years), adults (18-49), and elderly (50+).
  • By region, the market is divided into Asia-Pacific, North America, Europe, Latin America, and the MEA.

Prediabetes Market Regional Overview

According to the prediabetes industry analysis, the Asia-Pacific region is emerging as a significant growth market in the field of prediabetes due to several factors including rapid urbanization, changing lifestyles, and increasing prevalence of obesity. With a large and aging population, the region is experiencing a substantial rise in the incidence of prediabetes, driven by dietary shifts towards high-calorie, processed foods and sedentary lifestyles. As a result, there is a growing recognition among healthcare providers and policymakers in the Asia-Pacific region of the urgent need to address prediabetes as a precursor to type 2 diabetes and other chronic diseases. Moreover, the Asia-Pacific region is witnessing increasing awareness about the importance of preventive healthcare, prompting individuals to seek early detection and intervention for prediabetes. This heightened awareness is driving demand for diagnostic tests, screening programs, and lifestyle modification interventions aimed at managing prediabetes and reducing the risk of progression to type 2 diabetes.

Prediabetes Market Players

Some of the prominent prediabetes market companies are RESVERLOGIX, Valbiotis, Caelus Health, Novo Nordisk, Boston Therapeutics, SciMar, Aphaia Pharma, Bristol-Myers Squibb, and AstraZeneca.

Click here to buy the Premium Market Research report

Receive our personalized services and customization by clicking here

Mr. Frank Wilson

Acumen Research and Consulting

USA: +13474743864

India: +918983225533